Science Explorer Interactive view Map
Institution · Tokyo · Japan

Japan Arteriosclerosis Prevention Fund

doumyaku.jpROR OpenAlex
Research works
40
▼ 100% vs 2013–17
Citations
2.2k
54.8 per fractional work
Top-10% rate
24.1%
record average 16.5%
Open access
26%
world 28%

Not ranked overall: Japan Arteriosclerosis Prevention Fund is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

    Who are the top researchers at Japan Arteriosclerosis Prevention Fund?

    Ranked on the composite score, Hauss Wh lead among researchers whose main affiliation is Japan Arteriosclerosis Prevention Fund.

    1. 1 Hauss Wh Japan · #1,091,067 worldwide 18 citations · 35 works
    All ranked researchers at Japan Arteriosclerosis Prevention Fund

    Which keywords describe research at Japan Arteriosclerosis Prevention Fund?

    By fractional works in all years, weighted toward what it does more of than the world: Inflammation, Cancer, Angiogenesis, Atherosclerosis, Extracellular Matrix, Metabolic Syndrome, Cholesterol and Obesity.

    ▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

    Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

    All 40 words, with their numbers
    1. Inflammation13▲ 14×19 topics
    2. Cancer7▲ 12×8 topics
    3. Angiogenesis6▲ 39×6 topics
    4. Atherosclerosis6▲ 39×8 topics
    5. Extracellular Matrix5▲ 53×3 topics
    6. Metabolic Syndrome4▲ 13×10 topics
    7. Cholesterol4▲ 57×4 topics
    8. Obesity4▲ 14×7 topics
    9. Cardiovascular Disease4▲ 8.3×8 topics
    10. Cell Signaling4▲ 27×6 topics
    11. Statins4▲ 113×2 topics
    12. Cell Adhesion3▲ 84×1 topic
    13. Diabetes3▲ 14×5 topics
    14. Integrins3▲ 124×1 topic
    15. Insulin Resistance3▲ 15×4 topics
    16. Metabolism2▲ 9.6×6 topics
    17. C-Reactive Protein2▲ 71×2 topics
    18. Hemostasis2▲ 41×3 topics
    19. Cancer Progression2▲ 25×3 topics
    20. Glucose Metabolism2▲ 53×1 topic
    21. Hypercholesterolemia2▲ 109×2 topics
    22. Lifestyle Intervention2▲ 66×1 topic
    23. Matrix Metalloproteinases2▲ 34×1 topic
    24. Tissue Inhibitors of Metalloproteinases2▲ 157×1 topic
    25. Genetic Variants2▲ 25×2 topics
    26. Cardiovascular Disease Prevention2▲ 64×1 topic
    27. Cholesterol-lowering2▲ 100×1 topic
    28. Immune Response2▲ 8.1×1 topic
    29. Oxidized LDL2▲ 190×1 topic
    30. Regulatory T Cells2▲ 46×2 topics
    31. Hypertension2▲ 13×3 topics
    32. Cardiovascular Risk2▲ 12×3 topics
    33. Arrhythmias2▲ 30×2 topics
    34. Fatty Acid Synthase2▲ 103×1 topic
    35. Lipid Metabolism2▲ 103×1 topic
    36. Genetic Polymorphisms2▲ 46×3 topics
    37. Thrombosis1▲ 16×2 topics
    38. Arachidonic Acid1▲ 103×1 topic
    39. Cardiovascular Events1▲ 20×2 topics
    40. Epoxyeicosatrienoic Acids1▲ 103×1 topic

    Which research topics does Japan Arteriosclerosis Prevention Fund publish most on?

    By volume: Cell Adhesion Molecules Research, Diabetes, Cardiovascular Risks, and Lipoproteins, Protease and Inhibitor Mechanisms and Lipoproteins and Cardiovascular Health.

    Cell Adhesion Molecules …3Cell Adhesion Molecules Research: 3 fractional worksDiabetes, Cardiovascular…2Diabetes, Cardiovascular Risks, and Lipoproteins: 2 fractional worksProtease and Inhibitor M…2Protease and Inhibitor Mechanisms: 2 fractional worksLipoproteins and Cardiov…2Lipoproteins and Cardiovascular Health: 2 fractional worksAtherosclerosis and Cardiovascular Diseases: 2 fractional worksCancer, Lipids, and Metabolism: 2 fractional worksPlatelet Disorders and T…1Platelet Disorders and Treatments: 1 fractional worksEicosanoids and Hypertension Pharmacology: 1 fractional worksAntiplatelet Therapy and Cardiovascular Diseases: 1 fractional worksInflammatory mediators and NSAID effects: 1 fractional works
    Immunology and AllergyEndocrinology, Diabetes and MetabolismCancer ResearchSurgery5 others

    Area is fractional works; colour is the subfield each topic belongs to.

    1. 1 Cell Adhesion Molecules Research Immunology and Allergy 3 works
    2. 2 Diabetes, Cardiovascular Risks, and Lipoproteins Endocrinology, Diabetes and Metabolism 2 works
    3. 3 Protease and Inhibitor Mechanisms Cancer Research 2 works
    4. 4 Lipoproteins and Cardiovascular Health Surgery 2 works
    5. 5 Atherosclerosis and Cardiovascular Diseases Immunology 2 works
    6. 6 Cancer, Lipids, and Metabolism Cancer Research 2 works
    7. 7 Platelet Disorders and Treatments Hematology 1 works
    8. 8 Eicosanoids and Hypertension Pharmacology Biochemistry 1 works
    9. 9 Antiplatelet Therapy and Cardiovascular Diseases Cardiology and Cardiovascular Medicine 1 works
    10. 10 Inflammatory mediators and NSAID effects Pharmacology 1 works

    How open and international is its research?

    Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

    openly available26.1%not open73.9%

    World: 28% of research is openly available.

    with international co-authors40.1%domestic only59.9%

    World: 19% is written across borders.

    How has Japan Arteriosclerosis Prevention Fund's research output changed?

    Output in 2018–2022 was 100% lower than in 2013–2017.

    199020002010
    grewheldshrank

    The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

    Other research institutions in Tokyo

    All research institutions in Tokyo

    Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.